Trial Profile
A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of the Safety and Efficacy of Nutropin AQ [Somatropin (DNA Origin) Injection] for the Treatment of Growth Restriction in Children With Cystic Fibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Growth disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech
- 22 Oct 2014 New trial record